Why SOVI Vitality Complex?

SOVI Nutraceuticals understands the importance of vitality as you age, and we believe that you should feel younger then you really are. 

Didn't We Tell You We Are Doctor Recommended?

Dr. Alejandro Miquel, MD, MBA, FAAFP recommends Vitality Complex to those looking for an alternative to prescription medication for the relief of pain, inflammation, stress, or anxiety.

It's All In The Science

Vitality Complex™'s proprietary blend full spectrum phtyo-cannabinoids, help accomplish this by reducing pain and inflammation [2] [3] [4] [5], reducing stress [10], improving sleep [11], and helping to maintain and regulate brain health [6] [7] [8] [9], which are some of the major issues that come about as you age.

What Sets Us Apart 

Quality and Potency Assured

Our full spectrum hemp is quality and potency assured through the BIOVA Hemp™ certification. All batches of our products come with a full Cannabinoid Profile, Certificates of Analysis (COA) from reputable third-party laboratories, and are rigorously tested for terpenes, pesticides and heavy metals to insure the highest quality extracts.

We Use The Whole Plant

Vitality Complex™ uses a proprietary blend of full spectrum phyto-cannabinoids (whole plant). Research has shown that supplements derived from the whole plant rather than isolates or synthetic versions have a greater medicinal impact [1].

Our product is not forced dried, preserving the flavonoids, essences, terpenes and oils in our extract. We use a solventless CO2 extraction process, slowly extracting the essential oils at low temperatures to ensure the highest quality product.

Bioavailable Proprietary Formula

True bio-available capsule for consistent fast, full absorption.

Premium and Organic Ingredients

SOVI™ Nutraceuticals only uses premium, organically grown and processed full spectrum hemp for consistency in Vitality Complex™.

Compliantly Grown, Processed, Formulated and Manufactured Product

All processes are performed according to strict GMP standards never using toxic solvents or other chemicals. Our manufacturer and their partners follow "Good Manufacturing Practices" and have full control over quality and processes from the farm to customer to ensure the highest quality hemp product.



References:

[1] Ruth Galilly, Z. Yekhtin, and L. Hanus, "Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol," Pharmacology & Pharmacy 6 (February 2015): 75-85. doi:10.4236/pp.2015.62010

[2] R. Greco, V. Gasperi, M. Maccarrone, and C. Tassorelli, "The Endocannabionid System and Migraine," Experimental Neurology 224, no. 1 (2010): 85-91. https://www.sciencedirect.com/science/article/pii/S0014488610001159?via%3Dihub

[3] S. Maione, F. Piscitelli, L. Gatta, D. Vita, L. De Petrocellis, E. Palazzo, V. de Novellis, and V. Di Marzo, "Non-psychoactive Cannabinoids Modulate the Descending Pathway of Antinociception in Anaesthetized Rats through Several Mechanisms of Action," British Journal of Pharmacology 162, no. 3 (2011): 584. https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/j.1476-5381.2010.01063.x

[4] W. Xiong, T. Cui, K. Cheng, F. Yang, S. R. Chen, D. Willenbring, Y. Guan, H.L. Pan, K. Ren, Y. Xu, and L. Zhang, "Cannabinoids Suppress Inflammatory and Neuropathic Pain by Targeting α3 Glycine Receptors," Journal of Experimental Mdicine 209, no. 6 (2012): 1121-1134. http://jem.rupress.org/content/209/6/1121

[5] P. Nagarkatti, R. Pandey, S.A. Rieder, V.L. Hegde, and M. Nagarkatti, "Cannabinoids as Novel Anti-inflammatory Drugs," Future Medicinal Chemistry 1, no. 7 (2009): 1333-1349, http://doi.org/10.1016/j.cpr.2011.01.006

[6] Andras Bilkei-Gorzo, “The Endocannabinoid System in Normal and Pathological Brain Ageing,” Philosophical Transactions of the Royal Society of London 367, no. 1607 (2012): 3326–3341. https://royalsocietypublishing.org/doi/full/10.1098/rstb.2011.0388

[7] Ashok K. Shetty, "Promise of resveratrol for easing status epilepticus and epilepsy," Pharmacol Ther. 2011 Sep; 131(3): 269–286. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3133838/#

[8] J. Fernández-Ruiz, O. Sagredo, M. R. Pazos, C. García, R. Pertwee, R. Mechoulam, and J. Martínez-Orgado, “Cannabidiol for Neurodegenerative Disorders: Important New Clinical Applications for This Phytocannabinoid?” British Journal of Clinical Pharmacology 75, no. 2 (May 25, 2012): 323–333. https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2125.2012.04341.x

[9] Gary L. Wenk, “Animal Models of Alzheimer’s Disease,” Animal Models of Neurological Disease I (1992): 29–64, https://link.springer.com/protocol/10.1385%2F0-89603-208-6%3A29.

[10] A. R. Schier, N. P. Ribeiro, A. C. Silva, J. E. Hallak, J. A. Crippa, A. E. Nardi, and A. W. Zuardi, “Cannabidiol, a Cannabis sativa Constituent, As an Anxiolytic Drug,” Revista Brasileira de Psiquiatri 34, suppl. 1 (2012): S104–S110. PubMed PMID: 22729452. https://www.ncbi.nlm.nih.gov/pubmed/22729452

[11] Leonard Leinow and Juliana Birnbaum, "CBD - A Patient's Guide To Medical Cannabis," North Atlantic Books, Berkley, California (2017): 166-167.